Skip to main content
Top
Published in: Breast Cancer Research 1/2002

01-07-2002 | Meeting abstract

Changes in reporting practices with time when radiographers and radiologists double read screening mammograms

Authors: CB Eve, ERE Denton, M Ballantyne

Published in: Breast Cancer Research | Special Issue 1/2002

Login to get access

Excerpt

We have previously presented our experience of double reading screening mammograms by radiologists and trained radiographers. Our initial data showed that radiographers more readily detect calcification and smaller cancers compared to radiologists, who more readily detected larger cancers and higher grade tumours. To evaluate whether these differences have persisted with time, we have reviewed the last 4 years' data and compared the first 30,000 screening mammograms double read by radiographer and radiologist to the subsequent 30,000. The radiographers persistently detect malignant calcification more successfully than the radiologists. Differences in all other parameters have reduced. The group of film readers in our unit have not gravitated to a common mid point with time but have changed with time and reduced the differences in detection of all radiographic abnormalities except for calcification. We will present these data in detail and discuss possible reasons for persistent differences between the two groups of readers in detection of malignant calcification. …
Metadata
Title
Changes in reporting practices with time when radiographers and radiologists double read screening mammograms
Authors
CB Eve
ERE Denton
M Ballantyne
Publication date
01-07-2002
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2002
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr521

Other articles of this Special Issue 1/2002

Breast Cancer Research 1/2002 Go to the issue

Meeting abstract

Invasive cancer

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine